FDA NewsImmunotherapyNewsworthy

Cancer Immunotherapy Drugs Approved by the FDA Since 2015

This article includes immunotherapies approved through May 2017.
June 2017 Cancer Immunotherapy

Immunotherapies have been approved by the FDA for more than a decade, but the past 2 years stand out as the period when immunotherapy became a familiar concept in the United States, with the explosion of new therapies that involve the immune system approved by the FDA for many types of cancer.

The Table highlights cancer immunotherapy drugs approved by the FDA between January 2015 and May 2017, focusing on anti-PD-1 and anti-PD-L1 checkpoint inhibitors; antibodies such as monoclonal antibodies and anti-CTLA-4 antibodies; immunomodulatory drugs; and viral cancer therapies.

Cancer Immunotherapy Drugs Approved by the FDA Since 2015

Recommended For You
ImmunotherapyIssue Introductions
Immunotherapy Changing the Face of Cancer Care
By Dalia Buffery, MA, ABD
New developments in immunotherapy drugs continue to create buzz in the cancer community and beyond. This special issue discusses key developments in immunotherapy, highlighting new advances and providing resources for patients, their family members, and their oncology navigators.
ImmunotherapyLung Cancer
Immune Checkpoint Inhibitors Offer New Hope for Patients with Lung Cancer
Several immune checkpoint inhibitors are now approved for patients with non-small-cell lung cancer, giving hope to patients living with this disease.
CAR T-Cell Therapy a Promising Option for Patients with Certain Types of B-Cell Lymphoma
By Kristen Chanley
“CAR T-cell therapy provides an exciting and additional option for patients who have failed more traditional regimens,” says Dr. Gwen Nichols, Chief Medical Officer for Leukemia & Lymphoma Society.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.